Lupin has secured tentative FDA approval for apixaban oral suspension by filing a Paragraph III certification and will target a summer 2027 launch, getting ahead of tablet generics by nearly a year.
Lupin has secured tentative FDA approval for apixaban oral suspension by filing a Paragraph III certification and will target a summer 2027 launch, getting ahead of tablet generics by nearly a year.